Are all meningiomas from Depo-Provera cancerous?

No. Approximately 80% of meningiomas are WHO Grade I (benign). However, "benign" is misleading — even Grade I meningiomas can cause severe symptoms (seizures, vision loss, cognitive decline) and require major brain surgery. WHO Grade II (atypical, 15–20%) and Grade III (malignant, 1–3%) are more aggressive. All grades are included in the lawsuit.

How long do I need to have used Depo-Provera to qualify for a lawsuit?

Most studies show elevated risk beginning after 1 year of use, with the risk increasing significantly after 3 years. However, there is no strict minimum. If you received Depo-Provera injections and were diagnosed with a meningioma, you should consult an attorney regardless of how long you used the drug.

Can a meningioma shrink if I stop Depo-Provera?

Possibly. Because meningiomas are driven by progesterone receptor stimulation, removing the MPA stimulus by discontinuing Depo-Provera can slow growth or, in some cases, lead to tumor shrinkage. However, this is not guaranteed — many meningiomas continue to grow independently once established. Discontinuation should be combined with ongoing MRI monitoring.

I had a meningioma removed years ago. Can I still file a lawsuit?

Potentially yes. The statute of limitations in most states runs from when you knew or should have known about the connection between Depo-Provera and meningioma — not from the date of surgery. Since the FDA only added the meningioma warning in December 2025, many plaintiffs' discovery clocks may have started recently.

How long after stopping Depo-Provera can a meningioma appear?

Meningiomas are slow-growing tumors that may take years to reach detectable size. A meningioma could be diagnosed months or even years after the last Depo-Provera injection. The key factor is cumulative MPA exposure over the total period of use, not when the last injection occurred.

My meningioma is being monitored (watchful waiting). Do I have a case?

Yes. You do not need to have had surgery to file a claim. A diagnosed meningioma being monitored with serial MRI imaging is still a compensable injury. You face ongoing medical costs, anxiety about tumor growth, and the possibility of future surgery. Many watchful-waiting patients eventually require intervention.

I have headaches after years of Depo-Provera. Should I be worried?

New or worsening headaches — particularly persistent headaches that are different from your normal pattern — warrant medical evaluation. While most headaches are not caused by brain tumors, the combination of Depo-Provera history plus new neurological symptoms justifies requesting brain imaging (MRI). Early detection significantly improves treatment outcomes.

What are the symptoms of a Depo-Provera meningioma?

Common symptoms include persistent headaches that worsen over time, vision changes (blurred or double vision, visual field loss), seizures, hearing problems, weakness or numbness, cognitive decline, and personality changes. Symptoms develop gradually because meningiomas are slow-growing tumors. If you used Depo-Provera and experience any of these symptoms, request brain imaging from your doctor.

Can Depo-Provera meningioma cause seizures?

Yes. Seizures occur in over one-third of meningioma patients. A seizure in someone with a history of Depo-Provera use should prompt immediate brain imaging. If you experience a seizure — especially a first-ever seizure — go to the emergency room. The ER will typically perform brain imaging that can detect a meningioma.

What if my symptoms are mild — do I still have a case?

Yes. Even mild symptoms with a documented meningioma diagnosis are sufficient. Watchful-waiting cases (where the meningioma is monitored but not surgically removed) are compensable. You face ongoing medical monitoring costs, anxiety, quality-of-life impacts, and the risk that the tumor will grow and require future intervention.

How much is a Depo-Provera lawsuit worth?

No cases have settled or gone to trial yet. Based on comparable pharmaceutical brain injury litigation, projected values range from $75,000–$200,000 for monitored meningiomas, $200,000–$600,000 for surgical cases, and $600,000–$1,500,000+ for cases with permanent neurological damage. Actual values will depend on bellwether trial outcomes expected in 2026–2027.

I used Depo-Provera for 10 years. What is my risk?

Very high. The French BMJ study found a 5.6x increased risk for long-term users. The Frontiers review specifically recommended neurological monitoring for women with >10 years of use. With a decade of quarterly injections (40 injections totaling 6,000mg of MPA), your cumulative progestin exposure is enormous. Discuss screening with your doctor.

MDL 3140 is the multidistrict litigation that consolidates all federal Depo-Provera meningioma lawsuits in the Northern District of Florida under Judge M. Casey Rodgers. The MDL was established in February 2025. Consolidating cases allows for efficient pre-trial discovery and expert proceedings. Rule 702 hearings on general causation are scheduled for late May 2026.

Why didn't my doctor warn me about the brain tumor risk?

Until December 2025, the U.S. Depo-Provera label did not mention meningioma. Your doctor likely had no information about this risk from the drug's official prescribing information. This is precisely the failure-to-warn that the lawsuit addresses — Pfizer's delay in updating the U.S. label left both patients and providers uninformed.

Can I file if I used a generic version of Depo-Provera?

Generic versions contain the same active ingredient (medroxyprogesterone acetate / MPA) and carry the same meningioma risk. Named defendants include Pfizer as the brand manufacturer plus generic manufacturers including A-S Medication Solutions, Greenstone LLC, Prasco Laboratories, Pharmacia & Upjohn Company LLC, Preferred Pharmaceuticals Inc., and Viatris.

Can I recover damages for bone density loss too?

Potentially. If you suffered bone density loss alongside a meningioma, both injuries can be included in your claim. However, the bone density risk was disclosed via the 2004 black box warning, making the failure-to-warn argument stronger for meningioma (which had no U.S. warning until December 2025).

Should I wait for trial results before filing?

No. File as soon as possible. The statute of limitations is running regardless of the MDL timeline. Filing now ensures your case is in the pipeline when settlement programs are established. There is no advantage to waiting — and significant risk if you miss your filing deadline.

How long will the lawsuit take?

The Depo-Provera MDL is in early stages. Rule 702 hearings on general causation are scheduled for late May 2026. Bellwether trial selection will follow. The first trials may occur in late 2026 or 2027. Global settlement, if reached, could follow bellwether outcomes. From filing to resolution typically takes 2–5 years in pharmaceutical MDLs.

How is this different from the existing black box warning?

The 2004 black box warning is about bone mineral density loss (osteoporosis risk). The new December 2025 warning is specifically about meningioma brain tumors — a completely separate injury. Both are associated with long-term use, but they involve different mechanisms and different types of harm.

What percentage does the lawyer take?

Most Depo-Provera attorneys work on contingency — typically 33–40% of the recovery. You owe no fee upfront and the attorney only gets paid if you receive compensation. In MDL cases, there may also be a common benefit fund (typically 4–8%) that compensates attorneys who performed work benefiting all plaintiffs.

Pfizer is one of the world's largest pharmaceutical companies with 2024 revenue exceeding $58 billion. While Depo-Provera is not Pfizer's largest product, the company's deep pockets mean it has the ability to pay substantial settlements. Pfizer's corporate conduct — prioritizing revenue over timely label updates — is central to punitive damages arguments.

What about generic Depo-Provera manufacturers?

Generic manufacturers of MPA injectable contraceptive are also defendants in the MDL, including A-S Medication Solutions, Greenstone LLC (a Pfizer subsidiary), Prasco Laboratories, Pharmacia & Upjohn Company LLC, Preferred Pharmaceuticals Inc., and Viatris. If you used a generic version, you may have claims against the generic manufacturer.

Is the Mirena IUD safe after a meningioma diagnosis?

Discuss this carefully with your doctor. Mirena releases levonorgestrel (a different progestin from MPA). The EMA review focused primarily on high-dose MPA. However, given the progesterone receptor mechanism of meningiomas, many neurologists recommend avoiding all progestational hormones after a meningioma diagnosis. The copper IUD (Paragard) is a hormone-free alternative.

How quickly should I stop Depo-Provera if diagnosed with a meningioma?

The updated FDA label recommends discontinuing Depo-Provera immediately upon meningioma diagnosis. However, because Depo-Provera is a depot injection, the drug remains in your system for approximately 3 months after the last injection. You cannot "undo" a recent injection, but you should not receive any further injections. Discuss transition contraceptive options with your healthcare provider.

Will stopping Depo-Provera cause withdrawal symptoms?

Stopping Depo-Provera does not cause withdrawal in the traditional sense, but you may experience changes: return of menstrual periods (which may be irregular for 6–18 months), mood changes, possible weight changes, and gradual bone density recovery. These transition effects are generally manageable and far outweigh the risk of continued progestin exposure with a diagnosed meningioma.

Does filing a civil lawsuit affect my VA benefits?

No. VA disability benefits and civil lawsuit settlements are separate. You can pursue both simultaneously. VA benefits are not reduced by civil lawsuit recoveries. However, if you receive a civil settlement, you should consult a financial advisor about how it may affect other means-tested government benefits.

How do I get my military medical records showing Depo-Provera prescriptions?

Request your Service Treatment Records (STR) from the National Personnel Records Center (NPRC) using SF-180 form. If you receive VA healthcare, your VA medical file may also contain relevant records. Some records are available through the VA's Blue Button/MyHealtheVet online portal. Active duty members can access records through TRICARE and the Defense Health Agency.

My doctor says I don't need an MRI. What should I do?

If you have symptoms AND a history of Depo-Provera use, you can request a referral to a neurologist who can evaluate whether brain imaging is warranted. You can also reference the updated December 2025 FDA label, which instructs providers to "monitor patients on Depo-Provera CI for signs and symptoms of meningioma." If your doctor refuses, consider seeking a second opinion.

Depo-Provera Meningioma Brain Tumor - Depo-Provera Brain Tumor Lawsuits

People's Justice Research TeamUpdated February 20, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

What Is a Depo-Provera Meningioma?

A meningioma is a tumor arising from the meninges — the protective membranes surrounding the brain and spinal cord. Depo-Provera's active ingredient (medroxyprogesterone acetate) is a synthetic progestin that binds to progesterone receptors on meningioma cells, stimulating tumor growth. Meningiomas express progesterone receptors at rates of 60–80%, making them uniquely vulnerable to synthetic progestin stimulation.

Meningioma Risk by Duration of Use

The risk increases with cumulative Depo-Provera exposure: ≤1 year use: 23% increased risk; 1–3 years: 150% increased risk (OR 2.50); >3 years: up to 460% increased risk (OR 5.6 in the French BMJ study). This dose-response relationship is critical evidence in the litigation because it demonstrates a causal mechanism rather than a coincidental association.

Meningioma Types and Grades

WHO Grade I meningiomas (80%) are slow-growing and typically benign but can still cause serious symptoms requiring surgical intervention. WHO Grade II (atypical, 15–20%) are more aggressive with higher recurrence rates. WHO Grade III (malignant, 1–3%) are cancerous and carry the most severe prognosis. All grades are included in the litigation.

Treatment Options

Treatment depends on tumor size, location, and grade. Options include: craniotomy (surgical removal), stereotactic radiosurgery (Gamma Knife), radiation therapy, and active surveillance with serial MRI imaging. Many patients require ongoing neurological monitoring even after successful surgery due to recurrence risk.

Research & evidence

Scientific Evidence

Medroxyprogesterone Acetate and Meningioma: A Global Issue

Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health

View on PubMed

Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma

Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ

View on PubMed

The Association between Medroxyprogesterone Acetate Exposure and Meningioma

Griffin BR et al. (2024). Cancers

View on PubMed

FAQ

Frequently Asked Questions

37 QUESTIONS

Studies show that long-term use of Depo-Provera significantly increases the risk of meningioma — a tumor in the tissue surrounding the brain. The risk ranges from 1.5x to 5.6x depending on duration of use and the study population. Meningiomas express progesterone receptors at 60–80% rates, and the synthetic progestin in Depo-Provera (MPA) stimulates tumor growth by binding to these receptors.

Plaintiffs allege that the science linking progestins to meningioma dates to the 1980s, and that Canada warned about the risk in 2015 — a decade before the U.S. label was updated. Pfizer has stated it became aware of the meningioma association in 2023 and submitted a label supplement to the FDA in February 2024. However, plaintiffs argue Pfizer had a duty to investigate known progestin-meningioma links much earlier.

Not necessarily. In June 2026, Pfizer reached an agreement in principle to resolve the meningioma cases consolidated in the federal MDL, but the terms are still being finalized and no compensation amounts have been made public. How the settlement will treat claims filed after it was announced is one of the details still being worked out. Two things remain true regardless. State statutes of limitations still set firm deadlines to file, and those windows vary by state and by when a woman connected her tumor to Depo-Provera. And the agreement does not cover cases pending in state courts. Because resolutions like this are usually built around claims already on file, women who believe they qualify are generally advised to have their eligibility reviewed promptly rather than wait. People's Justice does not file claims or give legal advice — we investigate the reported link and connect people who may qualify with attorneys who handle these cases. No outcome is guaranteed.

Yes. Data shows that 41.2% of Black women and 27.2% of Hispanic women reported using Depo-Provera between 2015–2019, compared to 24.5% of the general population. The drug was marketed as a convenient option for low-income communities, and many women report feeling pressured toward it over other contraceptive choices. This disparity means the brain tumor risk falls disproportionately on communities of color.

Discuss this with your healthcare provider. The updated FDA label (December 2025) recommends that providers monitor patients for meningioma symptoms and discontinue if a meningioma is diagnosed. If you have been using Depo-Provera for more than 2 years, the FDA already recommends switching to another contraceptive method due to bone density concerns. Do not stop any medication without consulting your doctor.

Pfizer may try to argue it attempted to update the label in 2024 but was rejected by the FDA. However, this defense is weakened by several factors: Pfizer could have voluntarily added the warning through the CBE pathway without prior FDA approval, Canada warned in 2015 (9 years earlier), and the science linking progestins to meningioma dates to the 1980s. Pfizer's first label attempt in 2024 came only after the French BMJ study generated widespread media attention.

Potentially yes. If you received Depo-Provera during military service and were later diagnosed with a meningioma, you may establish service connection for VA disability benefits. You would need to demonstrate that the drug was prescribed during service and that the meningioma is connected to that treatment. A veteran service officer (VSO) or attorney specializing in VA claims can help navigate this process.

After initial meningioma detection, typical monitoring schedules include: MRI every 3–6 months for the first year, then every 6–12 months for years 2–5, then annually thereafter (for stable, non-surgical meningiomas). Surgical patients typically get an MRI 3 months post-surgery, then follow a similar surveillance schedule. Your neurosurgeon will customize the schedule based on tumor characteristics.

Insurance typically covers diagnostic MRI when ordered by a physician for symptoms. Screening MRI in asymptomatic patients may be harder to get covered. With the December 2025 FDA label update, physicians can now cite the official label recommendation to "monitor" for meningioma signs and symptoms as justification for imaging in symptomatic patients. Keep all bills — imaging costs are recoverable in your lawsuit.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the Depo-Provera Brain Tumor Investigation

Depo-Provera Brain Tumor LawsuitsDepo-Provera (medroxyprogesterone acetate / MPA) is a contraceptive injection given every three months. More than 5,830 lawsuits consolidated in MDL 3140 in the Northern District of Florida allege that Pfizer failed to warn about a significantly elevated risk of meningioma — a tumor in the tissue surrounding the brain and spinal cord. In June 2026, Pfizer reached an agreement in principle to resolve the federal MDL claims, though final terms and compensation amounts have not been disclosed and state-court cases are not covered. Women who received the shot for more than one year face up to a 5.6-fold increased risk, which rises with duration of use.CASE OVERVIEW

Depo-Provera Meningioma Brain Tumor

Quick Eligibility Review

Check your eligibility — free

What Is a Depo-Provera Meningioma?

Meningioma Risk by Duration of Use

Meningioma Types and Grades

Treatment Options

Scientific Evidence

Medroxyprogesterone Acetate and Meningioma: A Global Issue

Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma

The Association between Medroxyprogesterone Acetate Exposure and Meningioma

Frequently Asked Questions

What is the link between Depo-Provera and brain tumors?

Are all meningiomas from Depo-Provera cancerous?

How long do I need to have used Depo-Provera to qualify for a lawsuit?

Can a meningioma shrink if I stop Depo-Provera?

I had a meningioma removed years ago. Can I still file a lawsuit?

How long after stopping Depo-Provera can a meningioma appear?

My meningioma is being monitored (watchful waiting). Do I have a case?

I have headaches after years of Depo-Provera. Should I be worried?

What are the symptoms of a Depo-Provera meningioma?

Can Depo-Provera meningioma cause seizures?

Did Pfizer know about the meningioma risk?

Does the June 2026 settlement mean it's too late to file a Depo-Provera claim?

What if my symptoms are mild — do I still have a case?

How much is a Depo-Provera lawsuit worth?

I used Depo-Provera for 10 years. What is my risk?

What is MDL 3140?

Why didn't my doctor warn me about the brain tumor risk?

Can I file if I used a generic version of Depo-Provera?

Can I recover damages for bone density loss too?

Was Depo-Provera disproportionately prescribed to women of color?

Should I wait for trial results before filing?

Should I stop taking Depo-Provera?

How long will the lawsuit take?

How is this different from the existing black box warning?

What percentage does the lawyer take?

How big is Pfizer?

Can Pfizer argue the FDA rejected their label change attempt?

What about generic Depo-Provera manufacturers?

Is the Mirena IUD safe after a meningioma diagnosis?

How quickly should I stop Depo-Provera if diagnosed with a meningioma?

Will stopping Depo-Provera cause withdrawal symptoms?

Can I file a VA disability claim for a meningioma from Depo-Provera?

Does filing a civil lawsuit affect my VA benefits?

How do I get my military medical records showing Depo-Provera prescriptions?

My doctor says I don't need an MRI. What should I do?

How often should I get an MRI if a meningioma is found?

Does insurance cover MRI screening for Depo-Provera users?

Related Guides

Part of the Depo-Provera Brain Tumor Investigation